A Timeline of Australian Drug Scheduling

The Poisons Standard didn't arrive fully formed

Forty-seven separate pieces of colonial legislation. That's roughly what the Commonwealth inherited when it federated in 1901 , a patchwork of state pharmacy acts, poisons ordinances, and opium regulations, each drafted to fix a local problem that some other colony had already forgotten about. Understanding where we ended up requires knowing just how chaotic the starting point was.

I've spent more time than is probably healthy reading through archived Hansard transcripts of these debates. Between sea swims at Sandy Bay in winter, this is what passes for my idea of a good afternoon. Honestly, the arguments from 1905 about whether laudanum should require a pharmacist's signature sound almost identical to arguments still happening in Canberra a century later. Some things move slowly.

Federation to mid-century: competing standards and no real system

The Commonwealth Constitution gave the federal government limited powers over pharmaceutical regulation. For the first few decades, this meant state governments kept doing whatever they'd been doing, with minimal coordination. Victoria had one poisons schedule. New South Wales had another. Western Australia's framework diverged significantly from both.

The first real attempt at national coordination came through the Therapeutic Goods Act 1953, which established the basis for Commonwealth involvement in drug safety. But the legislation was modest by modern standards. It set out some quality requirements for imported medicines and gave the Health Department teeth to act on adulterated products. It did not yet create the scheduling architecture that Australians now navigate.

That architecture , the tiered schedule system , came progressively, largely in response to international treaty obligations. Australia ratified the United Nations Single Convention on Narcotic Drugs 1961, which required signatory countries to control listed substances through domestic legislation. The 1971 Convention on Psychotropic Substances extended that logic to a much broader class of compounds. Both treaties pushed Australia toward a coherent national framework, even if the political will to actually build one took another decade to materialise.

The Therapeutic Goods Administration and the modern scheduling era

The Therapeutic Goods Administration (TGA) was established within the federal Department of Health in 1989, following the Therapeutic Goods Act 1989. This is the piece of legislation that restructured how medicines are evaluated, listed, and registered in Australia; the foundation of the Australian Register of Therapeutic Goods (ARTG), which remains the central mechanism for market authorisation today. You can read more about the ARTG in our ARTG glossary entry.

The scheduling system itself is codified in the Poisons Standard, formally, the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). It is a legislative instrument made under the Therapeutic Goods Act, and it is the document that classifies every scheduled substance in Australia into one of ten schedules. The states and territories then adopt these schedules into their own poisons legislation, which is why the system has real legal effect across the country. The Commonwealth proposes; the states enforce.

The eight active schedules most people encounter run from Schedule 2 (pharmacy medicines, over-the-counter products kept behind the counter) through to Schedule 8 (Controlled Drugs), which covers substances like morphine and oxycodone that require strict prescription controls, records, and supply limits. Schedule 4 (Prescription Only) is the middle tier: not controlled drugs, but still requiring a valid prescription from an authorised health practitioner.

Schedule 9 is the category that generates the most public debate. These are Prohibited Substances; compounds for which there is considered to be no acceptable therapeutic use outside of narrowly approved research or clinical contexts. Criminal penalties apply to unauthorised supply or possession under state law.

Cannabis: a long road through the schedules

Cannabis is worth tracing in detail because it illustrates how scheduling decisions interact with science, politics, and public sentiment over time, and because the trajectory is genuinely unusual.

Through most of the twentieth century, cannabis and its constituent compounds were placed in Schedule 9. Tetrahydrocannabinol (THC), the principal psychoactive compound; remained prohibited. No accepted medical use, no legal pathway for patients.

The scientific landscape began to shift in the 1990s, when researchers characterised the endocannabinoid system, a signalling network present throughout mammalian biology, involving the CB1 and CB2 receptors, among other components. This discovery reframed cannabis pharmacology entirely. It was no longer simply a matter of a plant producing intoxication; there was a biological mechanism to study.

But discovery doesn't automatically change regulation. The scheduling review process has its own pace, and the TGA's evidence requirements don't adjust simply because academic interest increases. It took another two decades for the regulatory framework to catch up in any meaningful way.

In 2016, the TGA amended the Poisons Standard to move certain cannabis-derived medicines, including cannabidiol (CBD) under specific conditions; from Schedule 9 into Schedules 4 and 8, depending on the application and preparation. This created legal pathways for medical cannabis prescriptions through the Special Access Scheme (SAS) and the Authorised Prescriber framework. For the first time, a practitioner in Australia could legally access cannabis-derived preparations for a patient through a regulated mechanism.

A further rescheduling in 2021 moved low-dose CBD products to Schedule 3, meaning they could, in principle, be sold by a pharmacist without a prescription, subject to conditions. In practice, the path to compliant Schedule 3 CBD products reaching shelves has been slower than the regulation itself, largely because Good Manufacturing Practice (GMP) requirements and ARTG registration are significant hurdles for manufacturers to clear.

I'll say what I think here: the 2016 change was meaningful, but the implementation lag between rescheduling and actual patient access has been, at times, frustrating to observe from the outside. The structure is sound; the administrative machinery has not always kept pace with it.

Psychedelics: Schedule 9, then a narrow reclassification

Psilocybin and MDMA followed a broadly similar trajectory to cannabis, decades in Schedule 9, followed by a contested and partial rescheduling. In February 2023, the TGA made the decision to move psilocybin (for certain treatment-resistant conditions) and MDMA (for PTSD) from Schedule 9 to Schedule 8, effective 1 July 2023. This was not a general legalisation. It created a tightly bounded pathway: Authorised Prescribers only, under a specific regulatory approval granted by the TGA. Obtaining, using, or supplying these substances outside that framework remains a serious criminal offence under state and territory law.

The TGA's own summary is clear about the limitations. The evidence base consulted; including data from international trials, was assessed as promising but not conclusive, and the framework reflects that: controlled access, not open availability.

Peptides and the ongoing enforcement challenge

One area that often gets treated as outside the scheduling conversation is peptides, compounds built from chains of amino acids, linked by peptide bonds. Many peptides with research interest are in fact scheduled or unapproved in Australia, and the TGA has been active in enforcement action in recent years. Peptides marketed for performance enhancement or anti-ageing purposes frequently lack ARTG registration. Under Australian law, supplying unapproved therapeutic goods is illegal, and the TGA's enforcement team has made this an explicit priority. This isn't a grey area; it's a clear regulatory position that often gets underreported in the broader conversation about scheduling.

How the scheduling review process actually works

The TGA accepts scheduling proposals through a formal process, evaluated by the Advisory Committee on Medicines Scheduling (ACMS). Proposals can come from industry, health practitioners, researchers, or the public. The committee reviews the evidence according to criteria in the Poisons Standard itself, including toxicity, potential for misuse, and whether the substance has an accepted medical use.

It's worth understanding that scheduling decisions are not the same as efficacy approvals. Moving a substance from Schedule 9 to Schedule 4 means the TGA has determined there is a plausible medical use warranting controlled access, not that the evidence base is complete or that widespread prescribing is necessarily recommended. Those are different questions. I write about the difference between these regulatory signals and proof of effect in quite a bit of detail elsewhere on this site, because conflating them is one of the most common reading errors I see.

The Poisons Standard is updated continuously. It is not a fixed document. Changes made through TGA delegate decisions can take effect within weeks. Interim scheduling decisions can be made even faster when there's an urgent public health reason. The system is more dynamic than most people realise; which makes it important to check the current version of the Standard rather than relying on summaries that may be six months out of date.

Sources

• Poisons Standard (SUSMP), Therapeutic Goods Administration
• Scheduling Delegate's Final Decisions, TGA
• How Does Australia Classify Drugs?; Australian Drug Foundation
• Medicinal Cannabis Regulation, Australian Government Department of Health

, Hannah Bui, Evidence & Research-Literacy Writer